Media coverage about Ampliphi Biosciences Corp (NYSE:APHB) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ampliphi Biosciences Corp earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.6761896318335 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Ampliphi Biosciences Corp (NYSE:APHB) traded up 1.96% during trading on Friday, hitting $0.78. The stock had a trading volume of 56,631 shares. The company’s market capitalization is $6.82 million. Ampliphi Biosciences Corp has a 1-year low of $0.30 and a 1-year high of $38.25. The firm has a 50 day moving average of $0.89 and a 200 day moving average of $1.05.

ILLEGAL ACTIVITY NOTICE: “Ampliphi Biosciences Corp (APHB) Earns Media Impact Score of 0.16” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at

Ampliphi Biosciences Corp Company Profile

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with's FREE daily email newsletter.